AbCellera Overview

  • Founded
  • 2012
Founded
  • Status
  • IPO Registration
  • Employees
  • 76
Employees
  • Latest Deal Type
  • IPO
  • (Announced)
  • Latest Deal Amount
  • $200M
Latest Deal Amount
  • Investors
  • 15

AbCellera General Information

Description

Developer of monoclonal antibodies designed to accelerate the discovery and development of next-generation antibody therapies. The company's antibodies push therapeutic programs forward and fight disease, enabling healthcare researchers to get new avenues for human immune profiling and infectious disease research, with the potential to accelerate the development of urgently needed diagnostic tests and vaccines.

Contact Information

Ownership Status
In IPO Registration
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Primary Office
  • 2215 Yukon Street
  • Vancouver, British Columbia V5Y 0A1
  • Canada
+1 (604) 000-0000

AbCellera Timeline

2017201820192020
Financing RoundFinancing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

AbCellera Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
10. IPO 20-Nov-2020 $200M 00000 Announced Generating Revenue
9. Later Stage VC (Series B) 27-May-2020 00000 00000 Completed Generating Revenue
8. Grant 03-May-2020 00000 000.00 Completed Generating Revenue
7. Later Stage VC (Series A) 27-Sep-2018 0000 000.00 Completed Generating Revenue
6. Grant 25-Jan-2018 00000 Completed Generating Revenue
5. Grant 19-Jan-2017 00000 Completed Generating Revenue
4. Grant 26-Jun-2015 00000 00000 Completed Generating Revenue
3. Seed Round 09-Aug-2014 00000 Completed Generating Revenue
2. Grant 27-Sep-2013 $62K $725K Completed Generating Revenue
1. Capitalization 01-Jan-2012 $725K $725K Completed Startup
To view AbCellera’s complete valuation and funding history, request access »

AbCellera Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of monoclonal antibodies designed to accelerate the discovery and development of next-generation antibody ther
Biotechnology
Vancouver, Canada
76 As of 2019
00000
00000000 00000

00000000

tetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad
0000 000000000
San Francisco, CA
0 As of 0000
00000 00000

000000 0

cididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamc
0000000000000
South San Francisco, CA
000 As of 0000
00000
000000 - 000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

AbCellera Competitors (44)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Distributed Bio Venture Capital-Backed San Francisco, CA 0 00000 00000
000000 00000000000 Formerly VC-backed South San Francisco, CA 000 00000 000000 - 000 00000
000000 00000000000 Venture Capital-Backed Cambridge, MA 00 00000 00000 00000
000 0000000000000 Venture Capital-Backed Chester, United Kingdom 00 000.00 0000000000 0 000.00
000000 Venture Capital-Backed Lebanon, NH 000 00000 0000000000 0 00000
You’re viewing 5 of 44 competitors. Get the full list »

AbCellera Executive Team (10)

Name Title Board Seat Contact Info
Andrew Booth Chief Financial Officer
Veronique Lecault Co-Founder, Board Member & Chief Operating Officer
Tryn Stimart Chief Legal Officer and Corporate Secretary
Kathleen Lisaingo Ph.D Co-Founder and Group Leader, Cell Screening
Daniel Da Costa Co-Founder & Executive, Engineering
You’re viewing 5 of 10 executive team members. Get the full list »

AbCellera Board Members (8)

Name Representing Role Since
Carl Hansen Ph.D Self Co-Founder, Chief Executive Officer & Board Member 000 0000
John Hamer Ph.D Data Collective Board Member 000 0000
John Montalbano Self Board Member 000 0000
Michael Hayden Ph.D Self Board Member 000 0000
Peter Thiel JD Self Board Member 000 0000
You’re viewing 5 of 8 board members. Get the full list »

AbCellera Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

AbCellera Investors (15)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Eli Lilly Corporation Minority 000 0000 000000 0
Founders Fund Venture Capital Minority 000 0000 000000 0
Peter Thiel Angel (individual) Minority 000 0000 000000 0
Presight Capital Venture Capital Minority 000 0000 000000 0
University of Minnesota Endowment Limited Partner Minority 000 0000 000000 0
You’re viewing 5 of 15 investors. Get the full list »

AbCellera Investments & Acquisitions (4)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
0000000 18-Nov-2020 000000000000000000 0000 Drug Delivery 0000 000000 00.0
000000 30-Sep-2020 00000 00000 00 000.00 Other Commercial Services 0000 000000 00.0
000000000 (0000000 20-Aug-2020 000000000000000000 Biotechnology 0000 000000 00.0
Lineage Biosciences 01-Aug-2018 Merger/Acquisition Other Pharmaceuticals and Biotechnology 0000 000000 00.0
To view AbCellera’s complete investments and acquisitions history, request access »

AbCellera Subsidiaries (1)

Company Name Industry Location Founded
0000000 Drug Delivery San Francisco, CA 0000
To view AbCellera’s complete subsidiaries history, request access »